Publications

1. Lim KJC, Steinhardt M, Rees MJ, Greipp P, Kelemen K, Dispenzieri A, Jevremovic D, Baughn L, Buadi FK, Dingli D, Hayman SR, Kapoor P, Muchtar E, Leung N, Fonder A, Hobbs M, Hwa YL, Warsame R, Kourelis TV, Cook J, Binder M, Abdallah N, Zanwar S, Lin Y, Go RS, Siddiqui MA, Parrondo RD, Ailawadhi S, Ailawadi S, Roy V, Cooke R, Dun K, Zordan A, Ninkovic S, Best SH, Alatorre GA, Wiedmeier-Nutor JE, Kortum KM, Einsele H, Chhabra S, Bergsagel PL, Kyle RA, Gertz MA, Kumar SK, Rajkumar SV, Fonseca R, Gonsalves WI, Yadav U. A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement. Blood Adv. 2026 Jun 23; 10 (12):4286-4295
   View PubMed
2. Steinhardt MJ, Muchtar E, Kourelis T, Warsame R, Mauermann ML, Buadi FK, Dingli D, Leung N, Cook J, Go RS, Hayman SR, Gonsalves WI, Kapoor P, Zanwar S, Binder M, Hellou T, Tan M, Halawi H, Fonder A, Hobbs M, Abdallah N, Lin Y, Siddiqui MA, Kyle RA, Kortum KM, Einsele H, Rajkumar SV, Kumar SK, Gertz MA, Dispenzieri A. Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis. Blood Adv. 2026 Jun 9; 10 (11):4009-4019
   View PubMed
3. Steinhardt MJ, Hegenbart U, Hellou T, Oubari S, Roussel M, Schwotzer R, Buadi F, Dingli D, Binder M, Kourelis T, Zanwar SS, Rieger MJ, Morbach C, Cejka V, Gerber B, Stork S, Einsele H, Kumar S, Gertz M, Carpinteiro A, Kortum KM, Muchtar E, Dispenzieri A, Schonland S. Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis. Am J Hematol. 2026 Jun 7 Epub 2026 June 07
   View PubMed
4. Packard DG, Kumar SK, Dispenzieri A, Kapoor P, Janda G, Hellou T, Buadi FK, Dingli D, Zanwar S, Jevremovic D, Hayman SR, Leung N, Cook J, Abdallah N, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Siddiqui M, Christenson L, Hobbs M, Fonder A, Pak K, Lee LH, Lin Y, Gertz MA, Rajkumar SV, Gonsalves WI. Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia. Am J Hematol. 2026 Jun 3 Epub 2026 June 03
   View PubMed
5. Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D. Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data. Br J Haematol. 2026 Jun; 208 (6):2134-2142 Epub 2026 Apr 23
   View PubMed
6. Bohra A, Dasari S, Zanwar S, Gonsalves WI, Kapoor P, Binder M, Dispenzieri A, Timm MM, Buadi F, Jevremovic D, Rajkumar SV, Kumar S. Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma. Leukemia. 2026 Apr 22 [Epub ahead of print]
   View PubMed
7. Zanwar S, Abeykoon J, D'Sa S, Roos-Weil D, Larson DR, Colby CL, Durot E, Kastritis E, Uppal E, Tomkins O, Morel P, Mondello P, Montes L, Paludo J, Ailawadhi S, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Rajkumar SV, Quinquenel A, Dispenzieri A, Fonseca R, Gertz MA, Kumar S, Dimopoulos MA, Ansell SM, Treon S, Castillo JJ, Kapoor P. POD24 is a novel determinant of prognosis in patients with Waldenstrom macroglobulinemia. Blood Adv. 2026 Apr 14; 10 (7):2322-2327
   View PubMed
8. Mellgard GS, Bazarbachi AH, Zanwar S, Hegenbart U, Bodanapu G, Bhutani D, Chen G, D'Souza A, Dispenzieri A, Gertz M, Kumar S, Lentzsch S, Milani P, Muchtar E, Palladini G, Trajanova D, Patwari A, Sanchorawala V, Mohty M, Wang S, Kastritis E, Theodorakakou F, Schonland S, Chakraborty R, Cowan AJ. Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated Patients. Am J Hematol. 2026 Apr; 101 (4):768-783 Epub 2026 Mar 07
   View PubMed
9. Zanwar S, Kumar S, Rajkumar SV. Diagnosis, risk stratification and management of smouldering multiple myeloma. Nat Rev Clin Oncol. 2026 Apr; 23 (4):279-296 Epub 2026 Jan 22
   View PubMed
10. Muchtar E, Geyer S, Dispenzieri A, Grogan M, Kourelis TV, Buadi FK, Kapoor P, Dingli D, Gonsalves W, Leung N, Merlini G, Rosenthal J, Boilson B, Lyle M, Frantz JG, Hayman SR, Lacy MQ, Siddiqui M, Cook J, Abdallah N, Binder M, Zanwar S, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients. JACC CardioOncol. 2026 Apr; 8 (2):137-147
    View PubMed
11. Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, Kumar S. Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia. Leukemia. 2026 Apr; 40 (4):854
    View PubMed
12. Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, Gonsalves W, Seheult J, Otteson G, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Dasari S, Gertz MA, Kourelis T, Leung N, Lin Y, Muchtar E, Siddiqui M, Weivoda M, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma. Blood Cancer J. 2026 Jan 3; 16 (1):20 Epub 2026 Jan 03
    View PubMed
13. Zanwar S, Rajkumar SV. Measurable residual disease assessment in multiple myeloma. Leukemia. 2026 Jan; 40 (1):25-28 Epub 2025 Dec 05
    View PubMed
14. Hellou T, Kumar SK, Alouch SS, Almodovar-Diaz A, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Zanwar S, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Cook J, Binder M, Abdallah N, Lin Y, Go RS, Siddiqui MA, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia. Blood Cancer J 2025 Dec 27; 15 (1):215
    View PubMed
15. Tawfiq RK, Spears GM, Young JR, Mahowald M, Tobin WO, Patgunarajah U, Ruan GJ, Yi D, Zanwar S, Rech KL, Koster MJ, Acosta-Medina AA, Gruber LM, Ravindran A, Shah MV, Bennani NN, Alhaj Moustafa M, Hilal T, Sartori-Valinotti JC, Vassallo R, Ryu J, Davidge-Pitts C, Dasari S, Witzig TE, Go RS, Goyal G, Abeykoon JP. Cardiovascular Degeneration in Erdheim-Chester Disease: Prevalence, Burden, and Outcomes. Blood Adv. 2025 Aug 28 [Epub ahead of print]
    View PubMed
16. Chohan K, Paludo J, Dasari S, Novak JP, Abeykoon JP, Zanwar S, Yang ZZ, Jalali S, Bhardwaj V, Krull JE, Braggio E, Manske MK, Reeder CB, Ailawadhi S, Chanan-Khan A, Kapoor P, Kyle RA, Gertz MA, Novak AJ, Mondello P, Ansell SM. Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia. Haematologica. 2025 Dec 4 Epub 2025 Dec 04
    View PubMed
17. Zanwar S, Belge Bilgin G, Broski SM, Thorpe M, Bilgin C, Gonsalves W, Kapoor P, Kourelis T, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz MA, Leung N, Lin Y, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis. Leukemia. 2025 Dec; 39(12):2866-2871. Epub 2025 Sep 28.
    View PubMed
18. Bolarinwa A, Zanwar S, Abdallah N, Buadi FK, Hayman SR, Gertz MA, Dispenzieri A, Muchtar E, Kapoor P, Gonsalves W, Kourelis T, Dingli D, Warsame R, Leung N, Cook J, Binder M, Lin Y, Hwa Y, Rogers MG, Hobbs M, Fonder A, Jevremovic D, Rajkumar SV, Kumar SK. Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma. Am J Hematol. 2025 Dec; 100 (12):2286-2292 Epub 2025 Oct 04
    View PubMed
19. Bazarbachi AH, Zanwar S, Hegenbart U, Trajanova D, Bhutani D, Gertz MA, Dispenzieri A, Kumar S, D'Souza A, Patwari A, Cowan A, Chen G, Milani P, Palladini G, Sanchorawala V, Bodanapu G, Mohty M, Lentzsch S, Schonland SO, Muchtar E, Chakraborty R. Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era. Hemasphere. 2025 Dec; 9 (12):e70276 Epub 2025 Dec 28
    View PubMed
20. Zanwar S, Rajkumar SV. Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders. Leukemia. 2025 Nov; 39 (11):2610-2617 Epub 2025 July 23
    View PubMed
21. Hellou T, Packard DG, Atallah-Yunes SA, Orusa AM, Suzuki S, Kumar SK, Dispenzieri A, Zanwar S, Jevremovic D, Olteanu H, Horna P, Otteson G, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Cook J, Abdallah N, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Rajkumar SV, Gonsalves WI, Gertz MA. Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes. Blood Cancer J. 2025 Sep 29; 15 (1):152 Epub 2025 Sept 29
    View PubMed
22. Ravindran A, Jiang L, Ruan GJ, Dasari S, Abeykoon JP, Zanwar S, Young JR, Bach CR, McConathy JE, Bennani NN, Go RS, Goyal G, Rech KL. PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms. Leuk Lymphoma. 2025 Sep 25; 1-10 Epub 2025 Sept 25
    View PubMed
23. Muchtar E, Dispenzieri A, Buadi FK, Kapoor P, Dingli D, Kourelis TV, Gonsalves W, Leung N, Hayman SR, Lacy MQ, Siddiqui M, Cook J, Abdallah N, Binder M, Zanwar S, Hogan W, Warsame R, Rajkumar SV, Kumar SK, Gertz MA. From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis. Blood Adv. 2025 Aug 26; 9 (16):4311-4316
    View PubMed
24. Zanwar S, Novak J, Gonsalves W, Howe M, Braggio E, Rajkumar SV, Binder M, Jevremovic D, Dasari S, Kumar S. Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations. Blood Adv. 2025 Aug 12; 9 (15):3979-3987
    View PubMed
25. Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, Kumar S. Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia. Leukemia. 2025 Aug; 39 (8):2039-2041 Epub 2025 May 26
    View PubMed
26. Paludo J, Abeykoon JP, Perera ND, Sarosiek S, Gustine J, Ramirez-Gamero A, Varettoni M, Tedeschi A, Cavalloni C, Frustaci AM, Pederson LD, Zanwar SS, Kapoor P, Habermann TM, Witzig TE, Kyle RA, Gertz MA, Geyer SM, Treon SP, Castillo JJ, Ansell SM. Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100 (6):980-986 Epub 2025 Mar 10
    View PubMed
27. Sawalha Y, Sarosiek S, Welkie RL, Seif S, Thapa S, Zanwar S, Cahill K, Treitman R, Shah H, Arora S, Pongas G, Winter A, Major A, Riedell PA, Palomba ML, Kapoor P, Grajales-Cruz A, Shain KH, Thomas SK, Castillo JJ. Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia treated with venetoclax: a multicenter retrospective analysis. Blood Cancer J. 2025 Apr 15; 15 (1):65
    View PubMed
28. Bolarinwa A, Nagaraj M, Zanwar S, Abdallah N, Bergsagel PL, Binder M, Buadi F, Chhabra S, Cook J, Dingli D, Dispenzieri A, Gertz MA, Gonsalves W, Hayman S, Kapoor P, Kourelis T, Leung N, Lin Y, Muchtar E, Parrondo R, Roy V, Sher T, Siddiqui M, Warsame R, Fonder A, Hobbs M, Hwa YL, Rogers M, Yadav U, Wiedmeier-Nutor JE, Baughn LB, Vincent Rajkumar S, Fonseca R, Ailawadhi S, Kumar S. Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes. Blood Cancer J. 2025 Apr 04; 15(1):57.
    View PubMed
29. Acosta-Medina AA, Abeykoon JP, Zanwar S, Ruan GJ, Rech KL, Ravindran A, Bennani NN, Davidge-Pitts CJ, Koster MJ, Ryu JH, Shah MV, Tobin WO, Vassallo R, Young JR, Go RS, Goyal G, Mayo Clinic - University of Alabama at Birmingham Histiocytosis Working Group. Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants. Leukemia. 2025 Apr; 39 (4):991-994 Epub 2025 Feb 11
    View PubMed
30. Zanwar S, Kumar S. Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future. Leuk Lymphoma. 2025 Apr; 66 (4):573-583 Epub 2024 Dec 22
    View PubMed
31. Ho M, Paruzzo L, Minehart J, Nabar N, Noll JH, Luo T, Garfall A, Zanwar S. Extramedullary Multiple Myeloma: Challenges and Opportunities. Curr Oncol. 2025 Mar 20; 32 (3)
    View PubMed
32. Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, Gonsalves W, Otteson G, Bolarinwa AB, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz MA, Kourelis T, Leung N, Lin Y, Muchtar E, Warsame R, Fonder A, Hobbs M, Hwa YL, Rogers M, Kyle RA, Rajkumar SV, Kumar S. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma. Blood Cancer J. 2025 Feb 18; 15(1):20.
    View PubMed
33. Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D. Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy. Cancer Manag Res. 2025; 17:357-372 Epub 2025 Feb 19
    View PubMed
34. Chakraborty R, Zanwar S, Hegenbart U, Bhutani D, Gertz MA, Dispenzieri A, Kumar S, D'Souza A, Patwari A, Cowan A, Chen G, Milani P, Palladini G, Sanchorawala V, Bodanapu G, Schonland SO, Lentzsch S, Muchtar E. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy. Blood. 2024 Dec 19; 144 (25):2613-2624
    View PubMed
35. Smith KER, Acosta-Medina AA, Dasari S, Ranatunga W, Rech KL, Ravindran A, Young JR, McGarrah PW, Ruan GJ, Zanwar SS, Li JJ, Sartori-Valinotti JC, Snider JN, Witzig TE, Goyal G, Go RS, Abeykoon JP. Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations. JCO Precis Oncol. 2024 Nov; 8:e2400471 Epub 2024 Nov 22
    View PubMed
36. Chohan KL, Pruthi RK, Zanwar S, Paludo J, Go R, Pardanani A, Ashrani A, Cook JM, Thompson CA, Chanan-Khan A, Ailawadhi S, Habermann TM, Witzig TE, Gertz MA, Dingli D, Buadi FK, Dispenzieri A, Leung N, Kumar SK, Rajkumar V, Nichols WL, Kyle RA, Ansell SM, Kapoor P, Sridharan M, Abeykoon JP. The clinical impact of acquired von Willebrand syndrome secondary to Waldenstrom macroglobulinemia: an underrecognized source of major bleeding events. Leukemia. 2024 Nov; 38 (11):2497-2500 Epub 2024 Aug 28
    View PubMed
37. Smith KER, Acosta-Medina AA, Dasari S, Ranatunga W, Rech KL, Ravindran A, Young JR, McGarrah PW, Ruan GJ, Zanwar SS, Li JJ, Sartori-Valinotti JC, Snider JN, Witzig TE, Goyal G, Go RS, Abeykoon JP. Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations. Converted From Scientific Report. 2024 Nov; 8:e2400471. Epub 2024 Nov 22.
    View PubMed
38. Zanwar S, Galarza Fortuna GM, Sborov DW. Risk-adapted treatment in multiple myeloma: Does more make it merrier? Br J Haematol. 2024 Sep; 205 (3):767-769 Epub 2024 July 27
    View PubMed
39. Zanwar S, Kapoor P. Diagnosis and Risk Stratification in Waldenstrom Macroglobulinemia. J Natl Compr Canc Netw. 2024 Sep; 22 (7)
    View PubMed
40. Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, Kumar S, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P. Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42 (21):2527-2536 Epub 2024 May 24
    View PubMed
41. Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol 2024 Jun 6; 17 (1):42 Epub 2024 June 06
    View PubMed
42. Zanwar S, Gertz MA, Muchtar E, Buadi FK, Kourelis T, Gonsalves W, Go RS, Hayman S, Kapoor P, Binder M, Cook J, Dingli D, Leung N, Lin Y, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S, Dispenzieri A. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024 Jun; 38 (6):1423-1426 Epub 2024 Apr 09
    View PubMed
43. Ruan GJ, Zanwar S, Ravindran A, Schram S, Abeykoon JP, Hazim A, Young JR, Shah MV, Bennani NN, Jiang L, Morlote D, Rech KL, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. Am J Hematol. 2024 May; 99 (5):871-879 Epub 2024 Feb 26
    View PubMed
44. Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities. Eur J Haematol. 2024 Feb; 112 (2):197-210 Epub 2023 Aug 06
    View PubMed
45. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
46. Goyal G, Acosta-Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R, Ryu JH, Shah MV, Bennani NN, Young JR, Bach CR, Ruan GJ, Zanwar S, Tobin WO, Koster MJ, Davidge-Pitts CJ, Gruber LM, Dasari S, Rech KL, Go RS. Long-term outcomes among adults with Langerhans cell histiocytosis. Blood Adv. 2023 Nov 14; 7 (21):6568-6578
    View PubMed
47. Ravindran A, Dasari S, Ruan GJ, Artymiuk CJ, He R, Viswanatha DS, Abeykoon JP, Zanwar S, Young JR, Goyal G, Go RS, Rech KL, Mayo Clinic-The University of Alabama at Birmingham Histiocytosis Working Group. Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells. Mod Pathol. 2023 Oct; 36 (10):100268 Epub 2023 July 04
    View PubMed
48. Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, Kumar S. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023 Oct; 98 (10):1540-1549 Epub 2023 July 08
    View PubMed
49. Zanwar S, Jacob EK, Greiner C, Pavelko K, Strausbauch M, Anderson E, Arsana A, Weivoda M, Shah MV, Kourelis T. The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant. Blood Cancer J. 2023 Sep 26; 13 (1):151 Epub 2023 Sept 26
    View PubMed
50. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Mauermann M, Witzig TE, Johnston P, Kyle RA, King RL, Habermann TM, Kumar S, Kapoor P. Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenstrom macroglobulinemia. Leuk Lymphoma 2023 Jul-Aug; 64 (8):1490-1493 Epub 2023 June 10
    View PubMed
51. Zanwar S, Gertz MA, Muchtar E. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment. J Natl Compr Canc Netw. 2023 Jan; 21 (1):83-90
    View PubMed
52. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
53. Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, Morlote DM, King RL, Rummage C, Zanwar S, Acosta-Medina AM, Tobin WO, Shah MV, Bennani NN, Vassallo R, Ryu JH, Koster MJ, Davidge-Pitts CJ, Witzig TE, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status. JAMA Oncol. 2022 Dec 1; 8 (12):1816-1820
    View PubMed
54. Ho M, Xiao A, Yi D, Zanwar S, Bianchi G. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Curr Oncol. 2022 Nov 21; 29 (11):8975-9005
    View PubMed
55. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
56. Durot E, Kanagaratnam L, Zanwar S, Toussaint E, Kastritis E, D'Sa S, Alcoceba M, Tomowiak C, Hivert B, Protin C, Abeykoon JP, Vos JMI, Michallet AS, Rodier C, Dupuis J, Lepretre S, Merabet F, Roussel X, Zini JM, Regny C, Patel A, Morel P, Roos-Weil D, Treon SP, Dimopoulos MA, Garcia-Sanz R, Kapoor P, Castillo JJ, Delmer AJ. High frequency of central nervous system involvement in transformed Waldenstrom macroglobulinemia. Blood Adv. 2022 Jun 28; 6 (12):3655-3658
    View PubMed
57. Zanwar S, Abeykoon JP, Dasari S, Ravindran A, Young JR, Acosta-Medina AA, Rech KL, Schwartz J, Mangold A, Rosenthal A, Bennani NN, Shah MV, Morlote D, Goyal G, Go RS. Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer J 2022 Jun 28; 12 (6):97 Epub 2022 June 28
    View PubMed
58. Zanwar S, Ravindran A, Abeykoon JP, Young JR, Kozelsky TF, Rech KL, Goyal G, Go RS. Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma. Haematologica. 2022 Sep 1; 107 (9):2276-2279 Epub 2022 Sept 01
    View PubMed
59. Zanwar S, Abeykoon JP. Treatment paradigm in Waldenstrom macroglobulinemia: frontline therapy and beyond. Ther Adv Hematol. 2022; 13:20406207221093962 Epub 2022 Apr 29
    View PubMed
60. Ho M, Zanwar S, Duggan P, Carr R, Habermann T, Navin PJ, Salama ME, Parikh SA. Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma. Am J Hematol. 2022 Jan 01; 97(1):151-159. Epub 2021 Nov 01.
    View PubMed
61. Zanwar S, Kumar S. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. Leuk Lymphoma. 2021 Dec; 62 (13):3087-3097 Epub 2021 July 24
    View PubMed
62. Durot E, Kanagaratnam L, Zanwar S, Kastritis E, D'Sa S, Garcia-Sanz R, Tomowiak C, Hivert B, Toussaint E, Protin C, Abeykoon JP, Guerrero-Garcia T, Itchaki G, Vos JM, Michallet AS, Godet S, Dupuis J, Lepretre S, Bomsztyk J, Morel P, Leblond V, Treon SP, Dimopoulos MA, Kapoor P, Delmer A, Castillo JJ. A prognostic index predicting survival in transformed Waldenstrom macroglobulinemia. Haematologica. 2021 Nov 1; 106 (11):2940-2946 Epub 2021 Nov 01
    View PubMed
63. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Colby C, Larson D, Paludo J, He R, Warsame R, Greipp PT, King RL, Thompson CA, Witzig TE, Lacy MQ, Gonsalves W, Nowakowski GS, Dingli D, Go RS, Habermann TM, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Disease outcomes and biomarkers of progression in smouldering Waldenstrom macroglobulinaemia. Br J Haematol. 2021 Oct; 195 (2):210-216 Epub 2021 Aug 02
    View PubMed
64. Ho M, Zanwar S, Kapoor P, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Baudi F, Muchtar E, Leung N, Kourelis T, Warsame R, Fonder A, Hwa L, Hobbs M, Kyle R, Rajkumar SV, Kumar S. The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer J. 2021 Sep 22; 11 (9):158 Epub 2021 Sept 22
    View PubMed
65. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, Kumar S, Kapoor P. Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22
    View PubMed
66. Abeykoon JP, Hampel PJ, King RL, Wood AJ, Larson MC, Nowakowski KE, Zanwar SS, Dasari S, Ruan GJ, Ravindran A, Wellik LE, Paludo J, Link BK, Cerhan JR, Ansell SM, Nowakowski GS, Thompson CA, Maurer MJ, Wenzl K, Novak AJ, Wu X, Habermann TM, Witzig TE. The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica. 2021 Aug 1; 106 (8):2261-2264 Epub 2021 Aug 01
    View PubMed
67. Zanwar S, Al Saleh AS, Gertz M. 66-Year-Old Man With Recurrent Hypotension and Flank Pain. Mayo Clin Proc. 2021 Jun; 96 (6):1622-1627
    View PubMed
68. Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, Advani RH, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP. Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 Feb; 192 (3):542-550 Epub 2020 Nov 18
    View PubMed
69. Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J. 2020 Aug 22; 10 (8):84
    View PubMed
70. Seth S, Zanwar S, Vu L, Kapoor P. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. Curr Hematol Malig Rep. 2020 Apr; 15 (2):45-55
    View PubMed
71. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2020 Mar; 95(3):274-281. Epub 2019 Dec 31.
    View PubMed
72. Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020 Feb; 188 (3):394-403 Epub 2019 Aug 29
    View PubMed
73. Zanwar S, Abeykoon JP, Kapoor P. Novel Treatment Strategies in the Management of Waldenstrom Macroglobulinemia. Curr Hematol Malig Rep. 2020 Feb; 15 (1):31-43
    View PubMed
74. Zanwar S, Ansell SM. Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas. Leuk Lymphoma 2019 Nov; 60 (11):2599-2601 Epub 2019 May 01
    View PubMed
75. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia. J Clin Oncol. 2019 Jun 1; 37 (16):1403-1411 Epub 2019 Apr 16
    View PubMed
76. Zanwar S, Abeykoon JP, Kapoor P. Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. Curr Hematol Malig Rep. 2019 Apr; 14 (2):70-82
    View PubMed
77. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019 Mar; 33 (3):790-794 Epub 2018 Oct 12
    View PubMed
78. Zanwar S, Jain P, Gokarn A, Devadas SK, Punatar S, Khurana S, Bonda A, Pruthy R, Bhat V, Qureshi S, Khattry N. Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection. Transpl Infect Dis. 2019 Feb; 21 (1):e13017 Epub 2018 Nov 19
    View PubMed
79. Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, Gonsalves W, Muchtar E, Dingli D, Lacy MQ, Hayman SR, Buadi F, Warsame R, Kyle RA, Rajkumar V, Kumar S, Kapoor P. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019 Feb; 33 (2):531-536 Epub 2018 Sept 28
    View PubMed
80. Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Nov; 93 (11):1384-1393 Epub 2018 Oct 02
    View PubMed
81. Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma. Expert Rev Hematol. 2018 Oct; 11 (10):761-771
    View PubMed
82. Ostwal V, Sahu A, Zanwar S, Nayak L, Shrikhande SV, Shetty N, Gupta S, Ramaswamy A. Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Indian J Med Res. 2018 Sep; 148 (3):284-290
    View PubMed
83. Noronha V, Zanwar S, Joshi A, Patil VM, Mahajan A, Janu A, Agarwal JP, Bhargava P, Kapoor A, Prabhash K. Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm. Clin Oncol (R Coll Radiol). 2018 Jan; 30 (1):23-29 Epub 2017 Nov 24
    View PubMed
84. Zanwar S, Noronha V, Joshi A, Patil VM, Kaushal R, Chougule A, Janu A, Mahajan A, Kapoor A, Prabhash K. Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases. Indian J Cancer. 2017 Oct-Dec; 54 (4):678-680
    View PubMed
85. Bose S, Ramaswamy A, Sahu A, Shetty O, Zanwar SS, Mirani J, Nashikkar C, Ostwal V. Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. South Asian J Cancer. 2017 Jul-Sep; 6 (3):110-112
    View PubMed
86. Zanwar S, Goel M, Patkar S, Ramaswamy A, Shetty N, Ramadwar M, Ostwal V. A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy. J Gastrointest Cancer. 2017 Mar; 48 (1):100-102
    View PubMed
87. Joshi A, Zanwar S, Noronha V, Patil VM, Chougule A, Kumar R, Janu A, Mahajan A, Kapoor A, Prabhash K. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther. 2017; 10:1859-1863 Epub 2017 Mar 28
    View PubMed
88. Zanwar S, Noronha V, Joshi A, Patil VM, Chougule A, Kumar R, More S, Goud S, Janu A, Mahajan A, Prabhash K. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients. Indian J Cancer. 2017 Jan-Mar; 54 (1):280-284
    View PubMed
89. Ostwal V, Engineer R, Ramaswamy A, Sahu A, Zanwar S, Arya S, Chopra S, Bal M, Patil P, Desouza A, Saklani A. Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX? J Gastrointest Oncol. 2016 Dec; 7 (6):958-967
    View PubMed
90. Zanwar S, Ostwal V, Sahu A, Jain D, Ramaswamy A, Saklani A, Ramadwar M, Shetty N, Shrikande SV. Rectal GIST-Outcomes and viewpoint from a tertiary cancer center. Indian J Gastroenterol. 2016 Nov; 35 (6):445-449 Epub 2016 Oct 26
    View PubMed
91. Zanwar S, Joshi A, Noronha V, Patil VM, Sable N, Popat P, Menon S, Kothari R, Bhargava P, Kapoor A, Prabhash K. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis. Indian J Cancer. 2016 Oct-Dec; 53 (4):579-582
    View PubMed
92. Patil VM, Noronha V, Joshi A, Zanwar S, Ramaswamy A, Arya S, Mahajan A, Bhattacharjee A, Prabhash K. Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality? South Asian J Cancer. 2016 Oct-Dec; 5 (4):182-185
    View PubMed
93. Joshi A, Zanwar S, Shetty N, Patil V, Noronha V, Bakshi G, Prakash G, Menon S, Prabhash K. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India. Indian J Cancer. 2016 Apr-Jun; 53 (2):313-316
    View PubMed
94. Zanwar S, Ostwal V, Gupta S, Sirohi B, Toshniwal A, Shetty N, Banavali S. Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Ann Transl Med. 2016 Feb; 4 (4):74
    View PubMed
95. Patil VM, Joshi A, Noronha V, Sharma V, Zanwar S, Dhumal S, Kane S, Pai P, D'Cruz A, Chaturvedi P, Bhattacharjee A, Prabhash K. Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). Int J Surg Oncol. 2016; 2016:6923730 Epub 2016 Feb 03
    View PubMed